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was used to assess the population level public health and economic impact of
infant anti-pneumococcal vaccination. The alternatives compared were: no vacci-
nation (comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were:
child illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs)
gained. Effectiveness and utilities were obtained from literature. Local costs (ex-
pressed in 2011 $US) and epidemiology (data from 2009-2011) were obtained from
Panamá=s official databases. Univariate sensitivity analysis was performed. The
time horizon for total costs was one year and for outcomes was lifetime with a
discount rate of 3%. RESULTS: Results show that immunization is cost-saving
against no-vaccination. PCV-13 gained the highest number of QALYs (305) against
PCV-10 (191) and PCV-7 (168). PCV-13 prevented 629 illnesses and gained 334 LYs.
PCV-10 and PCV-7 prevented 392 and 359 illnesses and gained 208 and 182 LY=s,
respectively. Total costs of illness with PCV-13, PCV-10, PCV-7 and no vaccination
were $622,445, $777,878, $804,978 and $1,005,512, respectively. These results were
robust to variations in herd immunity and impact adjustments of PCV-10
immunogenicity. CONCLUSIONS: This is the first cost-effectiveness study for anti-
pneumococcal immunization in Panamá. Immunization strategies based on 7, 10
and 13-valent PCV=s may be cost-saving interventions compared to no vaccination.
PCV-13 dominates PCV-10 and PCV-7.
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OBJECTIVES: . Pneumococcal bacteremia and pneumonia are priority diseases for
public health in Guatemala since these are among the 10 most frequent causes of
hospitalizations and mortality in children under 4 years old. The aim of this study
was to estimate the cost-effectiveness of immunization strategies based on pneu-
mococcal conjugate vaccines (PCVs) in Guatemala, from an institutional
perspective.METHODS: . A decision tree steady state model was used to assess the
population level public health and economic impact of infant anti-pneumococcal
vaccination. The alternatives compared were: no vaccination (comparator), PCV-10
and PCV-13. The effectiveness measures were: illness avoided life years gained
(LYs) and quality-adjusted life years (QALYs) gained. Effectiveness and utilities
were obtained from literature. Local costs (expressed in 2011 $US) and epidemiol-
ogy (data from 2009-2011) were obtained from Guatemala=s official databases. Uni-
variate sensitivity analysis was performed. The time horizon for total costs was one
year and for outcomes was lifetime with a discount rate of 3%. RESULTS: . Results
show that immunization is cost-saving against no-vaccination. PCV-13 gained
more QALYs (7,569) against PCV-10 (5,824). PCV-13 prevented 5658 illnesses and
gained 8404 LYs, while PCV-10 prevented 4140 illnesses and gained 6465 LYs. Total
costs of illness with PCV-13, PCV-10 and no vaccination were $2,599,952, $3,071,811
and $5,534,657, respectively. These results were robust to variations in herd immu-
nity and impact adjustments of PCV-10 immunogenicity. CONCLUSIONS: . This is
the first cost-effectiveness study for anti-pneumococcal immunization developed
in Guatemala. Immunization strategies based on 10 and 13-valent PCV=s may be
cost-saving interventions. PCV-13 dominates PCV-10.
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OBJECTIVES: Rotavirus gastroenteritis (RVGE) is one of the most frequent diseases
among children aged 5 or younger. A general recommendation for rotavirus vacci-
nation in Germany does not exist so far, leading to a vaccination rate of 30%. This
analysis simulates the cost-effectiveness of a general rotavirus vaccination in Ger-
many using Rotarix™ from the perspective of the statutory health insurance (SHI).
METHODS:An existing Markov model on rotavirus infection in children (published
before) was adapted to the German situation. The model simulates costs and ef-
fects of rotavirus vaccination in a birth cohort of 699,301 children. In the model,
vaccine efficacy rates from international clinical trials were combined with Ger-
man epidemiology and cost data from the SHI perspective for 2011 (including SHI
reimbursed productivity losses of parents). The model assumes a vaccination rate
of 100% and discount rates of 3% for costs and effects. Results were tested for
robustness using sensitivity analyses. RESULTS: A 100% vaccination with Rotar-
ixTM could avoid approximately 156,000 RVGE cases and associated physician vis-
its as well as in-patient hospital stays. From the SHI perspective, this leads to cost
savings of 13.6 Mio € in total. The main factors responsible for these savings are
in-patient hospital stays avoided (64.1 Mio €), SHI reimbursed productivity losses of
parents (19.0 Mio €) and physician visits avoided (5.4 Mio €). On the other hand,
vaccination costs amount to additional 79.4 Mio €. Stability of results was most
sensitive with respect to epidemiological parameters (number of RVGE cases, in-
patient hospital cases) as well as productivity loss. CONCLUSIONS: A general™
vaccination against rotavirus in Germany can avoid severe diarrhea events in chil-
dren aged 5 and younger. Additional vaccination costs for the SHI are more than
outbalanced by cost savings through in-patient hospital stays, SHI reimbursed
productivity loss and physician visits avoided.
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OBJECTIVES: To estimate the cost of virologic failure with the treatment of etra-
virine and raltegravir in multi-experienced patients in the Brazilian National AIDS
Program. METHODS: Treatment regimens of etravirine and raltegravir were de-
fined by the guidelines of the Brazilian National AIDS Program. Upon virologic
failure, subsequent treatments were defined according to the same guidelines con-
sidering new drug combinations not yet used by the patients. Treatment costs
considered the cost of medication as purchased by the Brazilian government and
published on their website. As maraviroc, a rescue treatment, is not yet reimbursed
by the AIDS program, its price was defined by law. To estimate the total cost,
patient numbers were calculated by the number of capsules of raltegravir dis-
pensed in the past 96 weeks, and assumed the same for patients treated with
etravirine. Virologic failure was gathered from the phase III clinical trials of ralte-
gravir and etravirine at week 48 and week 96. RESULTS: The average cost of treat-
ment for multi-failure patients with etravirine was on average R$ 26.692,26 at week
48 of treatment compared to R$ 26.634,15 per patient treated with raltegravir. At
week 96, the average treatment cost per patient was R$ 56.810,59 for raltegravir and
R$ 53.904,30 for etravirine. Given that 3.942 patients received treatment in the
previous 98 weeks, around 1.301 patients will fail treatment with raltegravir and
630 with etravirine. The total cost of treating these patients is R$ 73 million for
raltegravir and R$ 34 million for etravirine. CONCLUSIONS: Despite a similar aver-
age cost at week 48, etravirine treatment is a more economic option for the treat-
ment of multi-failure patients compared to raltegravir, saving up to 50% of treat-
ment costs with virologic failure patients in the Brazilian National AIDS program
over 96 weeks. Virologic failure is therefore an important indicator to avoid subse-
quent treatment costs especially in the long-term.
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OBJECTIVES: The analysis aimed to evaluate the cost-effectiveness of 48-week
therapy with peginterferon alpha-2a (PegIFN-2a) in HBeAg-negative chronic hep-
atitis B (CHB) patients versus 48-week (short-term analysis) or 4-year (long-term
analysis) therapy with adefovir, entecavir or lamivudine from the public payer
perspective in Poland. METHODS: A life-time Markov model based on previously
published analysis was used. States encompassed treatment response (ALT nor-
malization), relapse, complications (compensated/decompensated cirrhosis, hep-
atocellular carcinoma, liver transplantation) and death. Quality-adjusted life years
(QALYs) were the measure of effectiveness. Short-term efficacy assessment was
based on the results of randomized clinical trials (RCTs) corrected for response
duration. Long-term efficacy data for nucleos(t)ide analogues (NAs) were derived
from other published models and RCTs extensions. Utilities and transition proba-
bilities (spontaneous response, relapse, complications, death) were derived from
published literature. Direct medical costs, i.e. costs of drugs and procedures used in
the treatment of CHB and its complications were obtained using a survey con-
ducted among Polish clinicians. In the base case analysis costs and benefits were
discounted at a 5% and 3.5% annual rate, respectively. The robustness of the results
was assessed using one-way, scenario and probabilistic sensitivity analyses.
RESULTS: The short and long-term analysis demonstrated that the use of
PegIFN-2a increased QALYs and life years gained (LYGs) compared to all investi-
gated NAs. In the short-term model PegIFN-2a decreased the costs of complica-
tions treatment and increased the overall costs due to drug acquisition cost. ICERs
for PegIFN-2a vs. lamivudine, adefovir or entecavir amounted to 43,621, 6,600 and
25,166 PLN/QALY, respectively (1€4 PLN). In the long-term model PegIFN-2a was
cost-saving and dominated adefovir, while ICERs vs entecavir and lamivudine
amounted to 5,385 and 73,857 PLN/QALY, respectively. Sensitivity analysis proved
these results to be robust. CONCLUSIONS: Peginterferon alfa-2a is cost-effective
when compared to adefovir, entecavir and lamivudine in Poland.
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OBJECTIVES:To estimate cost-effectiveness of the vaccination program with quad-
rivalent Human Papillomavirus (HPV 6, 11, 16, 18) recombinant vaccine for the
prevention of cervical intraepithelial neoplasia (CIN) and cervical cancer (CC) in
Russian health care. METHODS: Cost-effectiveness analysis of vaccination pro-
gram vs no vaccination was performed. The previously published model (R. Insinga
et al.) was adjusted for Russia. Rates of CIN and CC were simulated with and
without vaccination in a cohort of girls 12-13 years old. Time-horizon was 24 years.
100% vaccination coverage was assumed. Direct medical costs were estimated.
Outcomes measured were: the cost of averted CIN case and the cost per additional
life-year saved. RESULTS: The cost of introducing HPV vaccination program with
100% coverage of the target audience of 12-13 years old girls is 408,16 mln €
(16,282,34 bln rubles). In the absence of vaccination the costs of providing medical
care to patients with CIN and CC are 160,027 mln € (6, 36 bln rubles). Therefore the
overall costs in a vaccinated cohort were 481,14 mln € (16,285,25 bln rubles). HPV
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